NEW YORK, May 1 (GenomeWeb News) - Danish drug developer Santaris Pharma said today that it has created a MicroRNA Research Consortium in partnership with the Department for Medical Biochemistry and Genetics at the University of Copenhagen.
The new consortium is partially supported by a €1.3 million ($1.6 million) grant from the the Danish Advanced Technology Foundation. This will be matched by an additional €1.3 million from the
The consortium's first goal will be "to target microRNAs involved in human cancer and develop effective drugs that block their action," Santaris said.
The University will have the first right to patent new drug targets discovered in the partnership and Santaris will be responsible for the development and commercialization of antagonists of these targets as potential new cancer drugs.